The adenovirus used in the PeptiCRAd platform was VALO-mD901, genetically modified to express murine OX40L and CD40L and previously shown to elicit tumor growth control and systemic antitumor response in a murine model of melanoma (Ylösmäki et al., 2021). This evidence concerns the gene CD40LG and melanoma.